
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7046622/publications.pdf Version: 2024-02-01



RAI SENCUDTA

#	Article	IF	CITATIONS
1	Three Multicenter, Randomized, Doubleâ€Blind, Placebo ontrolled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 258-270.	5.6	237
2	Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 701-707.	0.9	152
3	Delay to diagnosis in axial spondyloarthritis: are we improving in the UK?: Fig. 1. Rheumatology, 2015, 54, kev288.	1.9	57
4	Serum Soluble Bone Turnover Biomarkers in Psoriatic Arthritis and Psoriatic Spondyloarthropathy. Journal of Rheumatology, 2015, 42, 21-30.	2.0	51
5	The assessment of ankylosing spondylitis in clinical practice. Nature Clinical Practice Rheumatology, 2007, 3, 496-503.	3.2	45
6	Prevalence and factors associated with disturbed sleep in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review. Rheumatology International, 2017, 37, 257-271.	3.0	42
7	BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing) Tj ETQq1 1 0.784314	rgBT /Ov	erlock 10 Tf 5 41
8	Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. Arthritis Research and Therapy, 2017, 19, 210.	3.5	40
9	Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. Rheumatology, 2013, 52, 261-266.	1.9	36
10	Recommendations for acquisition and interpretation of MRI of the spine and sacroiliac joints in the diagnosis of axial spondyloarthritis in the UK. Rheumatology, 2019, 58, 1831-1838.	1.9	35
11	Juvenile Versus Adult-onset Ankylosing Spondylitis — Clinical, Radiographic, and Social Outcomes. A Systematic Review. Journal of Rheumatology, 2013, 40, 1797-1805.	2.0	34
12	Measurement of patient-reported outcomes. 2: Are current measures failing us?. Journal of Medical Economics, 2019, 22, 523-530.	2.1	33
13	Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy. Rheumatology and Therapy, 2019, 6, 165-177.	2.3	32
14	Measurement of patient-reported outcomes. 1: The search for the Holy Grail. Journal of Medical Economics, 2019, 22, 516-522.	2.1	31
15	Axial spondyloarthritis 10 years on: still looking for the lost tribe. Rheumatology, 2020, 59, iv25-iv37.	1.9	29
16	Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort. Rheumatology, 2018, 57, 619-624.	1.9	28
17	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. Rheumatology, 2018, 57, 1982-1990.	1.9	26
18	Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study. Clinical and Experimental Rheumatology, 2017, 35, 571-578.	0.8	23

#	Article	IF	CITATIONS
19	Feasibility, Reliability, and Sensitivity to Change of Four Radiographic Scoring Methods in Patients With Psoriatic Arthritis. Arthritis Care and Research, 2014, 66, 311-317.	3.4	21
20	Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study. Journal of Rheumatology, 2019, 46, 701-709.	2.0	21
21	Biologics for treating axial spondyloarthritis. Expert Opinion on Biological Therapy, 2018, 18, 641-652.	3.1	20
22	Clinical Outcomes and Progression to Orthopedic Surgery in Juvenile―Versus Adultâ€Onset Ankylosing Spondylitis. Arthritis Care and Research, 2015, 67, 651-657.	3.4	19
23	Short-term Repeat Magnetic Resonance Imaging Scans in Suspected Early Axial Spondyloarthritis Are Clinically Relevant Only in HLA-B27–positive Male Subjects. Journal of Rheumatology, 2018, 45, 202-205.	2.0	18
24	Setting and maintaining standards for patient-reported outcome measures: can we rely on the COSMIN checklists?. Journal of Medical Economics, 2021, 24, 502-511.	2.1	18
25	The clinical utility of human leucocyte antigen B27 in axial spondyloarthritis. Rheumatology, 2018, 57, 959-968.	1.9	16
26	Physical therapy in axial spondyloarthritis: guidelines, evidence and clinical practice. Current Opinion in Rheumatology, 2020, 32, 365-370.	4.3	16
27	Sleep in ankylosing spondylitis and non-radiographic axial spondyloarthritis: associations with disease activity, gender and mood. Clinical Rheumatology, 2018, 37, 1045-1052.	2.2	15
28	Practical Approaches to Bone Marrow Fat Fraction Quantification Across Magnetic Resonance Imaging Platforms. Journal of Magnetic Resonance Imaging, 2020, 52, 298-306.	3.4	15
29	Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath. Clinical Rheumatology, 2020, 39, 1501-1504.	2.2	15
30	Determinants of Longitudinal Adherence in Smartphone-Based Self-Tracking for Chronic Health Conditions. , 2021, 5, 1-24.		13
31	Awareness of axial spondyloarthritis among chiropractors and osteopaths: findings from a UK Web-based survey. Rheumatology Advances in Practice, 2019, 3, rkz034.	0.7	12
32	A novel IMU-based clinical assessment protocol for Axial Spondyloarthritis: a protocol validation study. PeerJ, 2021, 9, e10623.	2.0	11
33	AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). BMC Rheumatology, 2019, 3, 19.	1.6	10
34	Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?. Rheumatology International, 2017, 37, 327-336.	3.0	9
35	Correlates of physical activity in adults with spondyloarthritis and rheumatoid arthritis: a systematic review. Rheumatology International, 2022, 42, 1693-1713.	3.0	9
36	A truly complementary approach: A qualitative exploration of complementary and alternative medicine practitioners' views of treating ankylosing spondylitis. Musculoskeletal Care, 2018, 16, 96-102.	1.4	7

#	Article	IF	CITATIONS
37	Back pain, ankylosing spondylitis and social media usage; a descriptive analysis of current activity. Rheumatology International, 2020, 40, 1493-1499.	3.0	7
38	Expanding the spectrum of inflammatory spinal disease: AS it was, as it is now. Rheumatology, 2013, 52, 2103-2105.	1.9	6
39	Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit. Rheumatology, 2022, 61, 734-742.	1.9	6
40	Living with ankylosing spondylitis: an open response survey exploring physical activity experiences. Rheumatology Advances in Practice, 2019, 3, rkz016.	0.7	5
41	The Future of Axial Spondyloathritis Treatment. Rheumatic Disease Clinics of North America, 2020, 46, 357-365.	1.9	5
42	COSMIN reviews: the need to consider measurement theory, modern measurement and a prospective rather than retrospective approach to evaluating patient-based measures. Journal of Medical Economics, 2021, 24, 860-861.	2.1	5
43	Delayed diagnosis in axial spondyloarthritis—how can we do better?. Rheumatology, 2021, 60, 4951-4952.	1.9	5
44	Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis. Rheumatology Advances in Practice, 2019, 3, rkz012.	0.7	4
45	Improving Scoring Precision and Internal Construct Validity of the Bath Ankylosing Spondylitis Disease Activity Index Using Rasch Measurement Theory. Journal of Rheumatology, 2020, 47, 354-361.	2.0	4
46	The Future of Axial Spondyloarthritis Rehabilitation: Lessons Learned From COVIDâ€19. Arthritis Care and Research, 2022, 74, 44-49.	3.4	4
47	Use of Complementary and Alternative Medicine in Axial Spondyloarthritis: A Qualitative Exploration of Self-Management. Journal of Clinical Medicine, 2019, 8, 699.	2.4	3
48	Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort. Journal of Clinical Medicine, 2019, 8, 281.	2.4	3
49	(Un)Spoken realities of living with axial spondyloarthritis: a qualitative study focused on couple experiences. BMJ Open, 2019, 9, e025261.	1.9	3
50	FRIO414â€SECUKINUMAB PROVIDES RAPID AND SIGNIFICANT IMPROVEMENT IN THE SIGNS AND SYMPTOMS ANKYLOSING SPONDYLITIS: PRIMARY (16-WEEK) RESULTS FROM A PHASE 3 CHINA-CENTRIC STUDY, MEASURE 5. , 2019, , .	OF	3
51	Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study. Rheumatology Advances in Practice, 2020, 4, rkaa015.	0.7	3
52	Evaluating patient-reported fatigue and serum biomarkers in axial spondyloarthritis. Rheumatology, 2020, 59, 3111-3113.	1.9	3
53	Understanding flare in axial spondyloarthritis: novel insights from daily self-reported flare experience. Rheumatology Advances in Practice, 2021, 5, rkab082.	0.7	2
54	P261 Early and accurate diagnosis of patients with axial spondyloarthritis using machine learning: a predictive analysis from electronic health records in the United Kingdom. Rheumatology, 2022, 61, .	1.9	2

#	Article	IF	CITATIONS
55	223. Delay to Diagnosis in Axial Spondyloarthritis: Are we Improving?. Rheumatology, 2014, 53, i143-i143.	1.9	1
56	Monitoring patients with ankylosing spondylitis on anti-TNF monotherapy: too much too often?. Scandinavian Journal of Rheumatology, 2017, 46, 330-331.	1.1	1
57	P274 Association of self-reported symptoms and behaviour in axSpA: initial analyses from the Project Nightingale study. Rheumatology, 2020, 59, .	1.9	1
58	Longitudinal profiling of the gut microbiome in patients with psoriatic arthritis and ankylosing spondylitis: a multicentre, prospective, observational study. BMC Rheumatology, 2020, 4, 60.	1.6	1
59	Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. Rheumatology Advances in Practice, 2021, 5, rkaa063.	0.7	1
60	P270 â€~Act on Axial SpA': a gold standard time to diagnosis. Rheumatology, 2022, 61, .	1.9	1
61	Challenges in the management and research of juvenile-onset ankylosing spondylitis. International Journal of Clinical Rheumatology, 2013, 8, 615-617.	0.3	0
62	I80. Why Measure Disease Activity and What Should we Aim to Achieve?. Rheumatology, 2014, 53, i17-i17.	1.9	0
63	154. Development of Local Guidelines for the Management of Patients on Biologic Therapy Following Exposure to or Infection with Varicella Zoster Virus. Rheumatology, 2014, 53, i117-i118.	1.9	0
64	84.â€∫Efficacy of As-Needed Rituximab in Patients with Rheumatoid Arthritis: A Single Centre Review of Routine Clinical Practice. Rheumatology, 2014, 53, i87-i87.	1.9	0
65	202 Performance of the Spade Tool to Identify Spondyloarthritis in Patients Referred to a Specialist. Rheumatology, 0, , .	1.9	0
66	Comment on: delay to diagnosis in axial spondyloarthritis: are we improving in the UK?: Reply. Rheumatology, 2016, 55, 1707-1708.	1.9	0
67	115. SURVIVAL ANALYSIS AND REASONS FOR DISCONTINUING OR SWITCHING TUMOUR NECROSIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHRITIS: FINDINGS FROM A REAL-LIFE UK COHORT. Rheumatology, 2017, 56, .	1.9	0
68	SPONDYLARTHROPATHIES (INCLUDING PSORIATIC ARTHRITIS)099. SMOKING EXPOSURE IS ASSOCIATED WI INCREASED DISEASE SEVERITY IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR ANKYLOSING SPONDYLITIS. Rheumatology, 2017, 56, .	ГН 1.9	0
69	E70. A QUALITATIVE EXPLORATION OF THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE THERAPI IN AXIAL SPONDYLOARTHRITIS: INFORMING A REDUCTION IN THE DELAY TO DIAGNOSIS. Rheumatology, 2017, 56, .	ES 1.9	0
70	I45. ANKYLOSING SPONDYLITIS: ANTI–TUMOUR NECROSIS FACTOR AND BEYOND. Rheumatology, 2017, 50	5,1.9	0
71	163 A multi-centre retrospective study to describe the real world effectiveness of golimumab for treating ankylosing spondylitis (AS) in UK clinical practice. Rheumatology, 2018, 57, .	1.9	0
72	O01 Do patients with axial spondyloarthritis who meet research criteria for fibromyalgia benefit from biologic therapy?. Rheumatology, 2018, 57, .	1.9	0

#	Article	IF	CITATIONS
73	Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort: reply. Rheumatology Advances in Practice, 2018, 2, rky037.	0.7	0
74	O36 Exploring NICE criteria for continuing biologic therapies in axial spondyloarthritis: what is a suboptimal response?. Rheumatology, 2019, 58, .	1.9	0
75	246 Safety and effectiveness of certolizumab pegol in axial spodyloarthritis in a real-world setting: a UK sub-analysis from a European non-interventional study. Rheumatology, 2019, 58, .	1.9	0
76	269 In axial spondyloarthritis, magnitude of improved disease activity after six months of biologic disease-modifying treatment may be more relevant to short-term functional outcome than achieving an inactive disease state. Rheumatology, 2019, 58, .	1.9	0
77	O33 Recommendations for acquisition and considerations for interpretation of MRI of the spine and sacroiliac joints in the investigation of axial spondyloarthritis in the UK. Rheumatology, 2019, 58, .	1.9	0
78	THU0377â€THE CARDIOVASCULAR ASSOCIATIONS WITH ENTHESITIS AND DACTYLITIS IN PATIENTS WITH SPONDYLOARTHRITIS: RESULTS FROM THE ASAS-COMOSPA STUDY. , 2019, , .		0
79	THU0408â€ACHIEVING DISEASE REMISSION IN AXIAL SPONDYLOARTHRITIS: A TWO-CENTRE RETROSPECTIVE ANALYSIS OF RELEVANT BASELINE PATIENT CHARACTERISTICS. , 2019, , .		0
80	BRITSpA at five. Rheumatology, 2020, 59, 699-701.	1.9	0
81	P269 Longitudinal patterns of pain distribution in axSpA patients: a retrospective cohort study. Rheumatology, 2020, 59, .	1.9	0
82	P271 An analysis of short-term repeat MRI scans of vertebral corner lesions in suspected early axSpA: defining the prevalence and evolution of clinically significant spinal lesions without concurrent SIJ changes on imaging. Rheumatology, 2020, 59, .	1.9	0
83	P284 Certolizumab pegol-treated patients with non-radiographic axSpA demonstrate improvements in sleep quality and other patient reported outcomes. Rheumatology, 2020, 59, .	1.9	0
84	P285 Using FITBITR for fitness monitoring in patients attending the AS residential course at RNHRD: it does make a difference!. Rheumatology, 2020, 59, .	1.9	0
85	P286 Examining the relationships between important other autonomy support, basic psychological need satisfaction and well-being in those with non-radiographic AxSpA. Rheumatology, 2020, 59, .	1.9	0
86	P263 Should we advocate biologic dose-reduction in patients with AxSpA?. Rheumatology, 2020, 59, .	1.9	0
87	Corrigendum to: An analysis of short-term repeat MRI scans of vertebral corner lesions in suspected early axSpA: defining the prevalence and evolution of clinically significant spinal lesions without concurrent SIJ changes on imaging. Rheumatology, 2020, 59, 2654-2654.	1.9	0
88	P177 Management of patients with axSpA: an audit against the NICE diagnosis and management of adults with spondyloarthritis quality standard, QS170, and clinical practice guidelines. Rheumatology, 2021, 60, .	1.9	0
89	P007 Service evaluation of the nurse-led telephone advice line in the wake of COVID-19: a report of audit and staff satisfaction. Rheumatology, 2021, 60, .	1.9	0
90	P181 Long-term improvement in axial spondyloarthritis clinical outcomes following 2-weeks of intensive education and rehabilitation: results from the Bath residential rehabilitation programme. Rheumatology, 2021, 60, .	1.9	0

#	Article	IF	CITATIONS
91	P097 Raised inflammatory markers with unclear cause; what do they tell us? An audit of patients presenting to rheumatology service at RNHRD, Bath. Rheumatology, 2021, 60, .	1.9	Ο
92	"Talking AS". International Journal of Integrated Care, 2014, 14, .	0.2	0
93	Exploring the Future Role of Self-Tracking Data in the Rheumatology Clinic. Studies in Health Technology and Informatics, 2019, 259, 33-38.	0.3	0